Company intelligence / Profile preview

Nasus Pharma

Tel Aviv-Jaffa, Central Dist., Israelnasuspharma.com ↗

Ownership: Public · NSRX
Development stage: Phase 2

Overview

Nasus Pharma is a clinical-stage biopharmaceutical company developing powder-based intranasal products using proprietary microsphere technology. Their approach enables rapid drug absorption—up to seven times higher than solution-based drugs within the first four minutes—making it suitable for life-threatening emergencies. Recent clinical results for their intranasal epinephrine product have been positive and were presented at a major scientific meeting in early 2025.

Therapeutic areas: OtherImmunologyInfectious Diseases
Modalities: Powder-based intranasal drug deliverySmall molecules (inferred from use of epinephrine and other acute drugs)
Industry: Biotech

Drug pipeline

7 assets

FMXIN002

6 more assets in the full pipeline.

Financials

Market cap: $25.1M
Total revenue: $0
Enterprise value: $13.3M

Beyond the preview

Go deeper on Nasus Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nasus Pharma.